Plasma levels of nitrates in patients with Parkinson's disease.
It has been suggested that nitric oxide (NO) could be implicated in the neuronal degeneration of substantia nigra compacta in patients with Parkinson's disease (PD). To ascertain the possible role of NO as risk factor for PD, we studied the plasma levels of nitrate (oxidation product that provides an indirect estimation of NO), in 68 PD patients and 68 matched-controls. The plasma levels of nitrate did not differ significantly between PD patient and control groups (44.5 +/- 2.46 and 44.8 +/- 2.67 mumol/l, respectively). They were not influenced by antiparkinsonian drug and they did not correlate with age at onset, duration, scores of the Unified Parkinson's Disease Rating scales and Hoehn and Yahr staging in the PD group. These data suggest that plasma levels of nitrate are apparently unrelated to the risk for PD.
Molina
J A
JA
Department of Neurology, Hospital Doce de Octubre, Madrid, Spain.
Jiménez-Jiménez
F J
FJ
Navarro
J A
JA
Ruiz
E
E
Arenas
J
J
Cabrera-Valdivia
F
F
Vázquez
A
A
Fernández-Calle
P
P
Ayuso-Peralta
L
L
Rabasa
M
M
D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D009566:Nitrates / Q000097:blood*; D009569:Nitric Oxide / Q000378:metabolism; D010300:Parkinson Disease / Q000097:blood*
D000978:Antiparkinson Agents; D009566:Nitrates; D009569:Nitric Oxide